DOCSLIB.ORG

Microbiological Profile of Telithromycin, the First Ketolide Antimicrobial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Microbiological Profile of Telithromycin, the First Ketolide Antimicrobial View metadata, citation and similar papers at core.ac.uk brought to you by CORE Paperprovided by 48Elsevier Disc - Publisher Connector Microbiological profile of telithromycin, the first ketolide antimicrobial D. Felmingham GR Micro Ltd, London, UK ABSTRACT Telithromycin, the first of the ketolide antimicrobials, has been specifically designed to provide potent activity against common and atypical/intracellular or cell-associated respiratory pathogens, including those that are resistant to b-lactams and/or macrolide±lincosamide±streptograminB (MLSB) antimicrobials. Against Gram- positive cocci, telithromycin possesses more potent activity in vitro and in vivo than the macrolides clarithromycin and azithromycin. It retains its activity against erm-(MLSB)ormef-mediated macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes and against Staphylococcus aureus resistant to macrolides through inducible MLSB mechanisms. Telithromycin also possesses high activity against the Gram-negative pathogens Haemophilus influenzae and Moraxella catarrhalis, regardless of b-lactamase production. In vitro, it shows similar activity to azithromycin against H. influenzae, while in vivo its activity against H. influenzae is higher than that of azithromycin. Telithromycin's spectrum of activity also extends to the atypical, intracellular and cell-associated pathogens Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae. In vitro, telithromycin does not induce MLSB resistance and it shows low potential to select for resistance or cross-resistance to other antimicrobials. These characteristics indicate that telithromycin will have an important clinical role in the Ahed empirical treatment of community-acquired respiratory tract infections. Bhed Clin Microbiol Infect 2001: 7 (Supplement 3): 2±10 Ched Dhed Ref marker Fig marker these agents. Resistance to penicillin, particularly among S. Table marker INTRODUCTION pneumoniae, H. influenzae and M. catarrhalis, has limited the Ref end Given the diverse etiology of community-acquired respiratory usefulness of both penicillins and cephalosporins. In addition, Ref start tract infections (RTIs) and the time required to establish a these agents do not offer activity against atypical pathogens. microbiological diagnosis, treatment is usually initiated Macrolide antimicrobials provide effective coverage against a empirically. In choosing appropriate antimicrobial therapy, much broader spectrum of respiratory pathogens and have the likely pathogens and their susceptibilities are major been particularly useful for the treatment of patients intolerant considerations. Streptococcus pneumoniae, Haemophilus influenzae, of b-lactams. However, resistance to macrolides among Gram- Moraxella catarrhalis and Streptococcus pyogenes are common positive cocci is increasing worldwide [1], and frequently bacterial causes of lower (LRTIs) and upper respiratory tract confers cross-resistance to all other antimicrobials of the infections (URTIs). Other organisms that are implicated less macrolide±lincosamide±streptograminB (MLSB) class. New frequently, but should also be considered, include Staphylo- extended-spectrum fluoroquinolones with improved activity coccus aureus and the so-called `atypical' pathogens ± Chlamydia against Gram-positive pathogens have recently been licensed pneumoniae, Mycoplasma pneumoniae and Legionella pneumophila ± for treatment of RTIs, but early reports of emerging resistance which are emerging as an important cause of community- urge caution in their use [2]. Furthermore, these agents are not acquired pneumonia (CAP). licensed for use in children. The usefulness of currently available antimicrobial agents New classes of antimicrobial are therefore required which that are widely prescribed for these infections is being provide effective coverage against the key pathogens but also compromised by the changing etiology of RTIs and, perhaps retain activity against resistant isolates. Of the new agents that most importantly, by the increasing prevalence of resistance to are currently in development, telithromycin (HMR 3647) ± the first of the ketolide antimicrobials ± appears particularly Corresponding author and reprint requests: D. Felmingham, GR promising in this regard. Micro Ltd, 7±9 William Road, London NW1 3ER, UK The in vitro activity of telithromycin has been tested against Tel.: 020 738 87320 Fax: 020 738 87324 approximately 10 000 isolates of key respiratory pathogens. E-mail: [email protected] Highly consistent results have been obtained from many # 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7 (Suppl. 3), 2±10 Paper 48 Disc Felmingham Microbiological profile of telithromycin 3 laboratories worldwide, although only a selection of these patients with otitis media caused by penicillin-resistant studies will be included in this article. pneumococci [6]. In vitro activity FACTORS INFLUENCING DETERMINATION OF We and others have tested the comparative in vitro activity of TELITHROMYCIN ACTIVITY IN VITRO telithromycin against penicillin-susceptible (MIC 4 0.12 When determining the in vitro activity of a compound relative mg/L), -intermediate (MIC 0.12±1 mg/L) and -resistant to other agents, it is important to consider any possible effects strains (MIC 5 2 mg/L) [4,7,8]. The results of these studies of laboratory conditions or media. suggest that telithromycin has more potent antipneumococcal For telithromycin, minimum inhibitory concentrations activity than any of the macrolides or other available (MICs) can be determined by either agar or broth dilution antimicrobials. The results of our study are presented in Table techniques [3]. Both techniques produce similar results (with 1 [4,9]. Against susceptible strains, telithromycin demonstrated the exception of anaerobes) and are minimally affected by the potent activity with an MIC90 of 0.015 mg/L. Its activity was choice of medium (Brain Heart infusion medium, Mueller± at least as high as that of clarithromycin, the most active of the Hinton broth or Isosensitest). The presence of divalent cations macrolides tested, and 4-fold greater than that of azithromycin. in the culture medium does not appear to influence Telithromycin's activity was unaffected by intermediate or full telithromycin MICs. Calcium ions (0±200 mg/L in the resistance to penicillin: MIC90 against resistant strains was presence of 20 mg/L magnesium) and magnesium ions (0± 0.008 mg/L. The activity of telithromycin and the macrolides 50 mg/L in the presence of 100 mg/L calcium) have little was also tested against these same susceptible strains in the effect on the activity of telithromycin. presence of CO2. In air enriched to 6% CO2, the MICs for all As seen with other antimicrobials, telithromycin MICs are tested compounds were slightly increased. Telithromycin and influenced by inoculum size: between 103 and 107 colony clarithromycin MIC values increased 2-to 3-fold.For forming units (cfu) there is an 8-fold difference in MICs azithromycin, the effect was much more pronounced with (increased MICs seen with higher inocula), while within the MIC values increasing approximately 16-fold. range 104±105 cfu, no more than a 2-fold difference is Macrolide resistance in S. pneumoniae occurs principally as a observed in telithromycin MICs. Telithromycin, like the result of one of two mechanisms: (i) target site modification macrolides, is somewhat less active in acidic media (pH 5.5) and (ii) efflux. Target site modification is genetically than in alkaline conditions (pH 8). However, over the range determined by the ermB (erythromycin A resistance methylase) 6.5±7.5, the typical pH of culture media, there is only a 2-to genes. The product of the ermB gene is an RNA methylase 4-fold variation in telithromycin activity. The presence of that modifies a key site of interaction of erythromycin A with CO2 can cause up to a 4-fold increase in telithromycin MICs the ribosomal RNA (reviewed by Leclercq and Courvalin determined on agar [3,4]. This effect is recognized for [10]). Expression of the methylase can be constitutive or macrolides, and occurs because the growth rates of S. inducible and results in cross-resistance to all MLSB anti- pneumoniae and H. influenzae are increased in the presence of microbials. Elimination of macrolides from the cell by an CO2 rather than by any effect of CO2 on acidity of the growth efflux pump (M-type resistance), encoded by the mefA gene medium. Telithromycin's activity against anaerobic organisms [11], only confers resistance to 14-and 15-memberedring is also influenced by CO2. Credito et al. [5] have shown that macrolides. The activity of telithromycin against strains of S. this effect can be overcome by using Oxyrase (Oxyrase Inc., pneumoniae resistant to erythromycin A through these Mansfield, OH, USA) in the culture to prevent the mechanisms has been tested in comparison with erythromycin introduction of CO2. A and the lincosamide, clindamycin [9] (Table 1). Telithro- mycin showed excellent activity (MIC range 0.06±1 mg/L) against strains of S. pneumoniae resistant to macrolides as a ACTIVITY AGAINST COMMON RESPIRATORY PATHOGENS result of target site modification (methylation). The corre- sponding values for erythromycin A and clindamycin were Streptococcus pneumoniae well in excess of any concentrations that could be attained Streptococcus pneumoniae is the predominant bacterial pathogen therapeutically. Telithromycin also demonstrated excellent of RTIs. Penicillin
Load more

Recommended publications
  • Ketek, INN-Telithromycin
    authorised ANNEX I SUMMARY OF PRODUCT CHARACTERISTICSlonger no product Medicinal 1 1. NAME OF THE MEDICINAL PRODUCT Ketek 400 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 400 mg of telithromycin. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Light orange, oblong, biconvex tablet, imprinted with ‘H3647’ on one side and ‘400’ on the other. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications authorised When prescribing Ketek, consideration should be given to official guidance on the appropriate use of antibacterial agents and the local prevalence of resistance (see also sections 4.4 and 5.1). Ketek is indicated for the treatment of the following infections: longer In patients of 18 years and older: • Community-acquired pneumonia, mild or moderate (see section 4.4). • When treating infections caused by knownno or suspected beta-lactam and/or macrolide resistant strains (according to history of patients or national and/or regional resistance data) covered by the antibacterial spectrum of telithromycin (see sections 4.4 and 5.1): - Acute exacerbation of chronic bronchitis, - Acute sinusitis In patients of 12 years and older: • Tonsillitis/pharyngitis caused by Streptococcus pyogenes, as an alternative when beta lactam antibiotics are not appropriateproduct in countries/regions with a significant prevalence of macrolide resistant S. pyogenes, when mediated by ermTR or mefA (see sections 4.4 and 5.1). 4.2 Posology and method of administration Posology The recommended dose is 800 mg once a day i.e. two 400 mg tablets once a day. In patients of 18 years and older, according to the indication, the treatment regimen will be: - Community-acquired pneumonia: 800 mg once a day for 7 to 10 days, Medicinal- Acute exacerbation of chronic bronchitis: 800 mg once a day for 5 days, - Acute sinusitis: 800 mg once a day for 5 days, - Tonsillitis/pharyngitis caused by Streptococcus pyogenes: 800 mg once a day for 5 days.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • E3 Appendix 1 (Part 1 of 2): Search Strategy Used in MEDLINE
    This single copy is for your personal, non-commercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, contact CJHP at [email protected] Appendix 1 (part 1 of 2): Search strategy used in MEDLINE # Searches 1 exp *anti-bacterial agents/ or (antimicrobial* or antibacterial* or antibiotic* or antiinfective* or anti-microbial* or anti-bacterial* or anti-biotic* or anti- infective* or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or clindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).kf,kw,ti. or (antimicrobial or antibacterial or antiinfective or anti-microbial or anti-bacterial or anti-infective or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or c lindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).ab. /freq=2 2 alamethicin/ or amdinocillin/ or amdinocillin pivoxil/ or amikacin/ or amoxicillin/ or amphotericin b/ or ampicillin/ or anisomycin/ or antimycin a/ or aurodox/ or azithromycin/ or azlocillin/ or aztreonam/ or bacitracin/ or bacteriocins/ or bambermycins/ or bongkrekic acid/ or brefeldin a/ or butirosin sulfate/ or calcimycin/ or candicidin/ or capreomycin/ or carbenicillin/ or carfecillin/ or cefaclor/ or cefadroxil/ or cefamandole/ or cefatrizine/ or cefazolin/ or cefixime/ or cefmenoxime/ or cefmetazole/ or cefonicid/ or cefoperazone/
    [Show full text]
  • Intracellular Penetration and Effects of Antibiotics On
    antibiotics Review Intracellular Penetration and Effects of Antibiotics on Staphylococcus aureus Inside Human Neutrophils: A Comprehensive Review Suzanne Bongers 1 , Pien Hellebrekers 1,2 , Luke P.H. Leenen 1, Leo Koenderman 2,3 and Falco Hietbrink 1,* 1 Department of Surgery, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] (S.B.); [email protected] (P.H.); [email protected] (L.P.H.L.) 2 Laboratory of Translational Immunology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; [email protected] 3 Department of Pulmonology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands * Correspondence: [email protected] Received: 6 April 2019; Accepted: 2 May 2019; Published: 4 May 2019 Abstract: Neutrophils are important assets in defense against invading bacteria like staphylococci. However, (dysfunctioning) neutrophils can also serve as reservoir for pathogens that are able to survive inside the cellular environment. Staphylococcus aureus is a notorious facultative intracellular pathogen. Most vulnerable for neutrophil dysfunction and intracellular infection are immune-deficient patients or, as has recently been described, severely injured patients. These dysfunctional neutrophils can become hide-out spots or “Trojan horses” for S. aureus. This location offers protection to bacteria from most antibiotics and allows transportation of bacteria throughout the body inside moving neutrophils. When neutrophils die, these bacteria are released at different locations. In this review, we therefore focus on the capacity of several groups of antibiotics to enter human neutrophils, kill intracellular S. aureus and affect neutrophil function. We provide an overview of intracellular capacity of available antibiotics to aid in clinical decision making.
    [Show full text]
  • Summary Report on Antimicrobials Dispensed in Public Hospitals
    Summary Report on Antimicrobials Dispensed in Public Hospitals Year 2014 - 2016 Infection Control Branch Centre for Health Protection Department of Health October 2019 (Version as at 08 October 2019) Summary Report on Antimicrobial Dispensed CONTENTS in Public Hospitals (2014 - 2016) Contents Executive Summary i 1 Introduction 1 2 Background 1 2.1 Healthcare system of Hong Kong ......................... 2 3 Data Sources and Methodology 2 3.1 Data sources .................................... 2 3.2 Methodology ................................... 3 3.3 Antimicrobial names ............................... 4 4 Results 5 4.1 Overall annual dispensed quantities and percentage changes in all HA services . 5 4.1.1 Five most dispensed antimicrobial groups in all HA services . 5 4.1.2 Ten most dispensed antimicrobials in all HA services . 6 4.2 Overall annual dispensed quantities and percentage changes in HA non-inpatient service ....................................... 8 4.2.1 Five most dispensed antimicrobial groups in HA non-inpatient service . 10 4.2.2 Ten most dispensed antimicrobials in HA non-inpatient service . 10 4.2.3 Antimicrobial dispensed in HA non-inpatient service, stratified by service type ................................ 11 4.3 Overall annual dispensed quantities and percentage changes in HA inpatient service ....................................... 12 4.3.1 Five most dispensed antimicrobial groups in HA inpatient service . 13 4.3.2 Ten most dispensed antimicrobials in HA inpatient service . 14 4.3.3 Ten most dispensed antimicrobials in HA inpatient service, stratified by specialty ................................. 15 4.4 Overall annual dispensed quantities and percentage change of locally-important broad-spectrum antimicrobials in all HA services . 16 4.4.1 Locally-important broad-spectrum antimicrobial dispensed in HA inpatient service, stratified by specialty .
    [Show full text]
  • ESCMID Online Lecture Library © by Author
    French team to win the European Championship © by author ESCMID Online Lecture Library Antistaphylococcal team to fight staphylococci Anti-staphylococcal Pristinamycine Staph 2016 Clindamycine Tigecycline Ceftaroline ceftobiprole © byDaptomycine author Linézolide Fluoroquinolone ESCMIDAminoside Online Lecture VancomycineLibrary Pénicilline M Antistaphylococcal team to fight staphylococci MRSA: b-lactam’exit © by author ESCMID Online Lecture Library Antistaphylococcal team to fight staphylococci MRSA: b-lactam’exit Vancomycine © by author ESCMID Online Lecture Library Antistaphylococcal team to fight staphylococci SARM : exit les péniM Vancomycine : excellent player… but old molecule, toxicity, side effects © by author ESCMID Online Lecture Library Antistaphylococcal team to fight staphylococci … anti-MRSA of the new century • Synergistine injectable: quinupristine/dalfopristine (2000) • Oxazolidinones: linezolid (2001), tedizolid (2015) • Lipopeptide: daptomycine (2006) • Glycylcycline: tigecyclin (2006) • New Cephalosporins : ceftaroline (2012), ceftobiprole (2015) • Lipoglycopeptides: telavancine, dalbavancine, oritavancine © by author Toxicity ComplexESCMID use Online Lecture Library No more available Antistaphylococcal team to fight staphylococci … anti-MRSA of the new century • Synergistine injectable: quinupristine/dalfopristine (2000) • Oxazolidinones: linezolid (2001), tedizolid (2015) • Lipopeptide: daptomycine (2006) • Glycylcycline: tigecyclin (2006) • New Cephalosporins : ceftaroline (2012), ceftobiprole (2015) • Lipoglycopeptides:
    [Show full text]
  • Screening and Identification Methods for Official Control of Banned Antibiotics and Growth Promoters in Feedingstuffs
    Screening and Identification Methods for official control of Banned Antibiotics and Growth promoters in Feedingstuffs SIMBAG FEED Competitive and sustainable growth programme (GROWTH) project G6RD-CT-2000-00413 Coordinator: Jacob de Jong RIKILT – Institute of Food Safety Wageningen, The Netherlands Method protocol for screening on (banned) antibiotics in complete feedingstuffs and milk replacers by the microbiological plate test Author : Harry van Egmond RIKILT – Institute of Food Safety, Wageningen, The Netherlands Workpackage : Microbiological screening system (WP 2) Workpackage leader: Harry van Egmond Date of deliverable : 14-07-2005 Harry van Egmond, 14-7-2005 1/10 Method protocol for screening on (banned) antibiotics in complete feedingstuffs and milk replacers by the microbiological plate test 1 SCOPE AND FIELD OF APPLICATION This method describes the screening on banned antibiotics in complete feeding stuffs and milk replacers by a microbiological 3-plate test. To recognize interference of (carry over) of veterinary medicines or high concentrations of avilamycin, three additional test plates (mentioned in appendix 1) are necessary. Screening on banned antibiotics (virginiamycin, tylosin, spiramycin, zinc bacitracin, avoparcin) in the presence of aminoglycosides, macrolides, furazolidon, tetracyclines or quinolones is impossible with the microbiological plate test. Furthermore high concentrations of metals (Cu, Zn) might interfere. The limit of detection of the method is 1 mg/kg for avoparcin, tylosin, spiramycin, virginiamycin and 3-5 mg/kg for zinc bacitracin. 2 PRINCIPLE The sample is extracted at low pH with a mixture of acetone, hydrochloric-acid (HCl) and water. After addition of phosphate buffer pH 6.5, and further extraction, the feed is centrifuged. The supernatant is adjusted to pH 6.0-6.5 and dispensed into wells in three different agar media.
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Linezolid Resistance in Staphylococci
    Pharmaceuticals 2010, 3, 1988-2006; doi:10.3390/ph3071988 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review Linezolid Resistance in Staphylococci Stefania Stefani *, Dafne Bongiorno, Gino Mongelli and Floriana Campanile Department of Microbiology, University of Catania, Via Androne 81, 95124 Catania, Italy; E-Mails: [email protected] (D.B.); [email protected] (G.M.); [email protected] (F.C.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +39-095-2504714; Fax: +39-095-2504733. Received: 29 April 2010; in revised form: 3 June 2010 / Accepted: 23 June 2010 / Published: 24 June 2010 Abstract: Linezolid, the first oxazolidinone to be used clinically, is effective in the treatment of infections caused by various Gram-positive pathogens, including multidrug resistant enterococci and methicillin-resistant Staphylococus aureus. It has been used successfully for the treatment of patients with endocarditis and bacteraemia, osteomyelitis, joint infections and tuberculosis and it is often used for treatment of complicated infections when other therapies have failed. Linezolid resistance in Gram-positive cocci has been encountered clinically as well as in vitro, but it is still a rare phenomenon. The resistance to this antibiotic has been, until now, entirely associated with distinct nucleotide substitutions in domain V of the 23S rRNA genes. The number of mutated rRNA genes depends on the dose and duration of linezolid exposure and has been shown to influence the level of linezolid resistance. Mutations in associated ribosomal proteins also affect linezolid activity. A new phenicol and clindamycin resistance phenotype has recently been found to be caused by an RNA methyltransferase designated Cfr.
    [Show full text]
  • Executive Summary
    SOU 1997:132 Executive summary During the accession negotiations with the European Union, Sweden was granted a derogation from community legislation to maintain national legislation within the area of feed additives of the groups antibiotics, chemotherapeutics, coccidiostats and growth promoters. In Sweden, the use of such substances is restricted to the purpose of curing or preventing diseases, i.e. used as veterinary medicines according to the Feedingstuffs Act of 1985. The Swedish government has appointed a commission to evaluate the hazards and risks associated with use of antimicrobial feed additives in animal production. Our conclusions can be summarised as follows: • Antibacterial feed additives have favourable economic effects on livestock production, but from a long term perspective these are questionable, especially regarding animal welfare and animal health. Antibacterial feed additives can, at levels permitted in feedingstuffs, be used for treatment or prevention of animal diseases, which is in violation of directive 70/524/EEC. • The quinoxalines and the nitroimidazoles are potentially genotoxic and may be regarded as an occupational hazard. • Halofuginone and the quinoxalines are toxic for target species. This is deleterious for animal well being. • The risk of increased resistance associated with the general use of antibacterials as feed additives are far from negligible and the potential consequences are serious for both animal and human health. Antibacterials that are presently not used as therapeuticals in human or veterinary medicine are valuable templates for future drugs. As emergence of resistance is considered to be a threat to animal and human health, all AFA should be restricted to medical and veterinary purposes.
    [Show full text]
  • 23S Rrna Base Pair 2057–2611 Determines Ketolide Susceptibility and Fitness Cost of the Macrolide Resistance Mutation 2058A3G
    23S rRNA base pair 2057–2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A3G Peter Pfister*†, Natascia Corti*†, Sven Hobbie*, Christian Bruell*, Raz Zarivach‡, Ada Yonath‡§, and Erik C. Bo¨ ttger*§ *Institut fu¨r Medizinische Mikrobiologie, Universita¨t Zu¨ rich, Gloriastrasse 30͞32, CH-8006 Zu¨rich, Switzerland; and ‡Department of Structural Biology, Weizmann Institute, Rehovot 76100, Israel Contributed by Ada Yonath, February 27, 2005 The 23S rRNA A2058G alteration mediates macrolide, lincosamide, Mycobacterium intracellulare (14), Mycobacterium avium (15, 16), and streptogramin B resistance in the bacterial domain and deter- Mycobacterium kansasii (17), Mycobacterium chelonae, Mycobacte- mines the selectivity of macrolide antibiotics for eubacterial ribo- rium abscessus (18), Helicobacter pylori (19–21), Brachyspira (Ser- somes, as opposed to eukaryotic ribosomes. However, this muta- pulina) hyodysenteriae (22), Propionibacterium spp. (23), and Strep- tion is associated with a disparate resistance phenotype: It confers tococcus pneumoniae (24). These mutations have been mapped to high-level resistance to ketolides in mycobacteria but only mar- the macrolide-binding pocket in the ribosomal tunnel, specifically ginally affects ketolide susceptibility in streptococci. We used 23S rRNA nucleotides 2057, 2058, and 2059 in the Escherichia coli site-directed mutagenesis of nucleotides within domain V of 23S numbering system. rRNA to study the molecular basis for this disparity. We show that Nucleotides 2058 and 2059 act as key contact sites for macrolide mutational alteration of the polymorphic 2057–2611 base pair from binding (2, 25). Site-directed mutagenesis has been used to analyze A-U to G-C in isogenic mutants of Mycobacterium smegmatis in detail the role of 23S rRNA nucleotides 2058 and 2059 in significantly affects susceptibility to ketolides but does not influ- drug-target interaction; these studies also alluded to the importance ence susceptibility to other macrolide antibiotics.
    [Show full text]
  • Critically Important Antimicrobials for Human Medicine – 5Th Revision. Geneva
    WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) Critically Important Antimicrobials for Human Medicine 5th Revision 2016 Ranking of medically important antimicrobials for risk management of antimicrobial resistance due to non-human use Critically important antimicrobials for human medicine – 5th rev. ISBN 978-92-4-151222-0 © World Health Organization 2017, Updated in June 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/ igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Critically important antimicrobials for human medicine – 5th rev. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]